Q-omics provides the consensus-scored ATP10B profile across patient tissues and cancer cell-line models. ATP10B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP10B is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, ATP10B RNA expression shows 17,956 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where ATP10B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP10B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP10B survival associations across molecular data types. ATP10B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP10B RNA expression–survival associations across cancer types. High ATP10B expression shows unfavorable associations in UVM, THCA and LGG, but favorable associations in MESO, LAML and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP10B RNA expression.
This table summarizes ATP10B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ATP10B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP10B shows lower tumor expression in HNSC and KIRC and higher tumor expression in LUAD, THCA, LUSC and BLCA. The LUAD box plot shows higher ATP10B RNA expression in tumor versus normal tissue (log2 FC = +1.910, t-test p < 0.001).
This table shows molecular features associated with ATP10B in patient tissues and cancer cell lines. In patient samples, ATP10B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP10B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and OESOPHAGUS.
